Dyne Therapeutics, Inc.

NasdaqGS:DYN Rapport sur les actions

Capitalisation boursière : US$2.9b

Dyne Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Dyne Therapeutics est John Cox, nommé en Mar2024, a un mandat de 2.17 ans. La rémunération annuelle totale est $ 2.08M, composée du salaire de 34.7% et des bonus 65.3%, y compris les actions et options de la société. détient directement 0.1% des actions de la société, d'une valeur de $ 2.89M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.5 ans et 6.5 ans.

Informations clés

John Cox

Directeur général

US$2.1m

Rémunération totale

Pourcentage du salaire du PDG34.72%
Durée du mandat du directeur général2.2yrs
Propriété du PDG0.1%
Durée moyenne d'occupation des postes de direction1.5yrs
Durée moyenne du mandat des membres du conseil d'administration6.5yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • May 21

Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission

Summary Dyne Therapeutics, Inc. retains a Strong Buy rating, driven by clinical progress in DM1 and DMD programs targeting significant unmet needs. DYN expects to file a BLA for z-rostudirsen in DMD exon 51 skipping patients in Q2 2026, with potential commercialization by Q1 2027. Top-line data from the phase 1/2 ACHIEVE REC study in DM1 is anticipated in Q1 2027, supporting future accelerated approval filings. With $972.2M in cash as of March 2026, DYN is funded into Q1 2028, mitigating near-term financing risk. Read the full article on Seeking Alpha
Article d’analyse • Jun 17

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 13

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Summary Positive biomarker and functional data released from phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1. Data from registration cohort phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1, expected in the 1st half of 2026. With positive data released from phase 1/2 ACHIEVE study, plus FDA allowing splicing correction as a surrogate biomarker, it sets up a possible Accelerated Approval filing of DYNE-101 in 2026. It is said that the global Myotonic Dystrophy treatment market could reach $2.78 billion by 2033. Read the full article on Seeking Alpha
Article d’analyse • Feb 28

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 24

Dyne Therapeutics: Moving Forward On 2 Key Fronts

Summary Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. The company is advancing two primary candidates that have the potential to be approved over the next few years. The stock has fallen significantly recently as have myriad clinical stage concerns over the past few months. An updated analysis around Dyne Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Article d’analyse • Nov 12

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Dyne...
Seeking Alpha • Nov 11

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Summary Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significant improvement over Sarepta's Eteplirsen in Phase 1/2 trials, potentially accelerating approval and boosting DYN's stock. Key risks include executive reshuffling and potential hidden issues with IP, but current data and market potential make DYN attractive for speculative investors. DYN’s current cash runway of 3.5 years mitigates dilution risks, though further funding might be necessary if expenses ramp up with late-stage clinical trials. Despite recent leadership changes causing a stock selloff, DYN's strong cash position and potential in DMD present a speculative “Buy” opportunity ahead of its November 13 earnings report. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Summary Dyne Therapeutics, Inc. experienced a dramatic rise from $6.5 to $46 per share in 2024 followed by a sharp 45% drop to ~$24, now stabilizing at ~$34. The company's IPO in September 2020 raised $268m, focusing on therapeutics for muscle diseases like DM1, DMD, and FSHD. Positive Phase 1/2 trial results for DYNE-101 and DYNE-251 spurred the stock's surge, showing significant improvements in splicing correction and dystrophin expression. Recent volatility raises questions about a “buy the dip” opportunity or the end of Dyne's bull run, amid ongoing clinical trials and fundraising efforts. Read the full article on Seeking Alpha
Article d’analyse • Aug 14

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • May 21

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Summary Dyne Therapeutics stock rallied 27% after reporting positive results from the DELIVER and ACHIEVE trials. DYNE-101 showed dose-dependent benefits in patients with myotonic dystrophy type 1, indicating disease-modifying potential. DYNE-251 demonstrated positive results in the treatment of Duchenne muscular dystrophy, but long-term safety data is still needed. Financially, Dyne is strong, planning a $300 million public offering to extend its cash runway. I maintain a "hold" on DYN stock; it fits well in a barbell investment strategy for high-risk/high-return portfolio allocation. Read the full article on Seeking Alpha
Article d’analyse • May 04

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 05

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Summary Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2033. Results from the phase 1/2 DELIVER study, using DYNE-251, for the treatment of patients with Duchenne Muscular Dystrophy, expected in H2 2024. The global Duchenne Muscular Dystrophy treatment market is expected to reach $4.32 billion by 2029. Read the full article on Seeking Alpha
Article d’analyse • Dec 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse • Aug 09

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d’analyse • Mar 26

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Article d’analyse • Dec 10

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Aug 26

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 12

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics (NASDAQ:DYN), a clinical-stage biotech focused on muscular diseases, said on Tuesday that health authorities in New Zealand cleared a clinical trial application to start a Phase 1/2 for DYNE-101, an experimental therapy for myotonic dystrophy type 1 (DM1). DM1 is a rare genetic disease characterized by its impact on skeletal, cardiac, and smooth muscle. The multiple ascending dose trial is expected to start dosing patients in mid-2022, the company said, noting that more countries could greenlight DYNE-101 as the trial expands globally, targeting about 60 to 70 adult patients with DM1 The decision from the New Zealand Medicines and Medical Devices Safety Authority marks the “first regulatory clearance for DYNE-101, an important milestone in our efforts to execute our planned global clinical trial for people living with DM1,” Chief Executive of Dyne (DYN) Joshua Brumm said. Wall Street stands strongly behind the prospects of Dyne (DYN) with four Buy ratings and no Hold or Sell ratings.

Analyse de la rémunération des PDG

Comment la rémunération de John Cox a-t-elle évolué par rapport aux bénéfices de Dyne Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Mar 31 2026n/an/a

-US$452m

Dec 31 2025US$2mUS$721k

-US$446m

Sep 30 2025n/an/a

-US$424m

Jun 30 2025n/an/a

-US$413m

Mar 31 2025n/an/a

-US$367m

Dec 31 2024US$21mUS$537k

-US$317m

Rémunération vs marché: La rémunération totale de John ($USD 2.08M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 7.02M ).

Rémunération et revenus: La rémunération de John a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

John Cox (62 yo)

2.2yrs
Titularisation
US$2,076,868
Compensation

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 25, 2024. He also serves as Atlas Advisor at Atlas Venture Advisors, Inc. (formerly k...

Équipe de direction

NomPositionTitularisationCompensationPropriété
John Cox
CEO, President & Director2.2yrsUS$2.08m0.10%
$ 2.9m
Erick Lucera
CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer1.2yrsUS$2.83m0.075%
$ 2.2m
Oxana Beskrovnaya
Chief Innovation Officer1.1yrsUS$992.63k0.048%
$ 1.4m
Johanna Friedl-Naderer
Chief Commercial Officer1.7yrsUS$1.09m0.015%
$ 430.7k
Douglas Kerr
Chief Medical Officer1.7yrsUS$1.06m0.011%
$ 312.4k
Axel Wiest
Senior VP and Head of Portfolio Strategy & Operations1.3yrspas de donnéespas de données
Rajesh Manchanda
Chief Technical Officer1.1yrspas de donnéespas de données
James Bilotta
Chief Digital & Information Officer1.1yrspas de donnéespas de données
Daniel Wilson
Senior VP & Head of Legal3.3yrspas de donnéespas de données
Lucia Celona
Chief Human Resource Officer1.7yrspas de donnéespas de données
Debra Feldman
Chief Regulatory Affairs Officer6yrspas de donnéespas de données
Vikram Ranade
Chief Business Officer1.1yrspas de donnéespas de données
1.5yrs
Durée moyenne de l'emploi
58yo
Âge moyen

Gestion expérimentée: L'équipe de direction de DYN n'est pas considérée comme expérimentée (ancienneté moyenne 1.5 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
John Cox
CEO, President & Director2.2yrsUS$2.08m0.10%
$ 2.9m
Sudhir Agrawal
Member of Scientific Advisory Boardno datapas de donnéespas de données
Edward Hurwitz
Independent Director7.5yrsUS$317.01k0%
$ 0
David Lubner
Independent Director6.2yrsUS$334.51k0%
$ 0
Jason Rhodes
Independent Chairman8.4yrsUS$354.51k0%
$ 0
Dirk Kersten
Independent Director7.5yrsUS$334.51k0%
$ 0
Francesco Muntoni
Member of Scientific Advisory Board5.8yrspas de donnéespas de données
Louis Kunkel
Member of Scientific Advisory Boardno datapas de donnéespas de données
Nancy Andrews
Member of Scientific Advisory Boardno datapas de donnéespas de données
Catherine Stehman-Breen
Independent Director6.9yrsUS$327.01k0.054%
$ 1.6m
Charles Thornton
Member of Scientific Advisory Boardno datapas de donnéespas de données
Jeffrey Statland
Member of Scientific Advisory Board6yrspas de donnéespas de données
6.5yrs
Durée moyenne de l'emploi
62yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de DYN sont considérés comme expérimentés (ancienneté moyenne 6.5 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/25 15:01
Cours de l'action en fin de journée2026/05/22 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Dyne Therapeutics, Inc. est couverte par 21 analystes. 13 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Brian SkorneyBaird
William PickeringBernstein
Keay NakaeChardan Capital Markets, LLC